Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marek Minarik

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Anticancer Research|July 15, 2009
Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking statusMilos Pesek, Lucie Benesova, Barbora Belsanova, et al.
Anticancer Research|September 10, 2014
The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected]Ondrej Fiala, Milos Pesek, Jindrich Finek, et al.
Pathology Oncology Research : POR|October 27, 2018
Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic CancerLucie Benesova, Tereza Halkova, Bohus Bunganic, et al.
Anticancer Research|June 13, 2014
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinibOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|December 27, 2011
Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced diseaseMilos Pesek, Marta Kopeckova, Lucie Benesova, et al.
Anticancer Research|March 16, 2016
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line ChemotherapyMartin Svaton, Ondrej Fiala, Milos Pesek, et al.
Anticancer Research|May 16, 2009
Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancerCyril Salek, Petra Minarikova, Lucie Benesova, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 23, 2015
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutationOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Electrophoresis|October 23, 2010
A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPAMarek Minarik, Marcus Gassman, Barbora Belsanova, et al.
Genetic Testing and Molecular Biomarkers|August 4, 2009
Low prevalence and variable clinical presentation of troponin I and troponin T gene mutations in hypertrophic cardiomyopathyKarol Curila, Lucie Benesova, Martin Penicka, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Anticancer Research|July 15, 2009
Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking statusMilos Pesek, Lucie Benesova, Barbora Belsanova, et al.
Anticancer Research|September 10, 2014
The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected]Ondrej Fiala, Milos Pesek, Jindrich Finek, et al.
Pathology Oncology Research : POR|October 27, 2018
Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic CancerLucie Benesova, Tereza Halkova, Bohus Bunganic, et al.
Anticancer Research|June 13, 2014
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinibOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|December 27, 2011
Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced diseaseMilos Pesek, Marta Kopeckova, Lucie Benesova, et al.
Anticancer Research|March 16, 2016
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line ChemotherapyMartin Svaton, Ondrej Fiala, Milos Pesek, et al.
Anticancer Research|May 16, 2009
Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancerCyril Salek, Petra Minarikova, Lucie Benesova, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 23, 2015
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutationOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Electrophoresis|October 23, 2010
A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPAMarek Minarik, Marcus Gassman, Barbora Belsanova, et al.
Genetic Testing and Molecular Biomarkers|August 4, 2009
Low prevalence and variable clinical presentation of troponin I and troponin T gene mutations in hypertrophic cardiomyopathyKarol Curila, Lucie Benesova, Martin Penicka, et al.
Pageof 6